Jordan

Population 2018  10 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>0.5 (0.38–0.63)</td>
<td>5 (3.8–6.3)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>&lt;0.01 (&lt;0.01–0.011)</td>
<td>0.04 (0.01–0.11)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>0.036 (0.014–0.068)</td>
<td>0.36 (0.14–0.68)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.012 (&lt;0.01–0.017)</td>
<td>0.12 (0.08–0.17)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0 (0–&lt;0.01)</td>
<td>0.01 (0–0.02)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis 25%
- % with known HIV status 86%
- % pulmonary 71%
- % bacteriologically confirmed 46%
- % children aged 0–14 years 9%
- % women 46%
- % men 45%

Total cases notified 404

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 80% (63–100)
TB patients facing catastrophic total costs 3% (2–4)

TB/HIV care in new and relapse TB patients, 2018

- % with known HIV status who are HIV-positive 3 <1%
  - on antiretroviral therapy 3 100%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance
- New cases 73%
- Previously treated cases 40%

Laboratory-confirmed cases* MDR/RR-TB: 1, XDR-TB: 0

Patients started on treatment** MDR/RR-TB: 1, XDR-TB: 1

MDR/RR-TB cases tested for resistance to second-line drugs 0

Treatment success rate and cohort size

- New and relapse cases registered in 2017 56% 526
- Previously treated cases, excluding relapse, registered in 2017 91% 11
- HIV-positive TB cases registered in 2017 0
- MDR/RR-TB cases started on second-line treatment in 2016 33% 3
- XDR-TB cases started on second-line treatment in 2016 0

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment 100%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2019

National TB budget (US$ millions) 2.3
Funding source: 26% domestic, 37% international, 37% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-04-11 Data: www.who.int/tb/data